As reported on NBC News, an ophthalmologist with a history of criticizing the U.S. government’s Covid-19 vaccine strategy is emerging as a leading contender to
My name is Maha, and I had the privilege of being my father’s — my Baba’s — caregiver. I’ll be blunt; it was tough. When
Johnson & Johnson announced promising long-term efficacy and safety data for Icotyde (icotrokinra), the first and only targeted oral peptide that precisely blocks the IL-23
As reported on PharmaBiz, Roche has secured CE mark approval for its Elecsys Neurofilament Light Chain (NfL) assay, a blood-based test designed to help detect
Astrocytoma and glioblastoma are fast-growing brain cancers that often return after surgery, with survival for astrocytoma patients averaging only four to five months. While medications
Lynk Pharmaceuticals announced a significant development in its pipeline with the China National Medical Products Administration (NMPA) formally accepting the New Drug Application (NDA) for
I’ve always been a nature lover. I like nothing better than going for a hike in the woods or strolling along the beach or gazing
Editor’s Note: Patient Worthy is honored to share this submission by Regina Portnoy, a clinical researcher with 20 years of experience working alongside patients. Many
Daiichi Sankyo and Merck announced a significant regulatory milestone with the FDA’s acceptance and Priority Review of ifinatamab deruxtecan (I-DXd), a potentially first-in-class therapeutic targeting
As reported on BioPharmaDive, Roche is restarting efforts to get Elevidys, a gene therapy for Duchenne muscular dystrophy (DMD), approved in Europe by launching a
I’ve always been an overachiever – someone who puts their mind to something and delivers more than was expected, someone who strives for greatness. I
IDEAYA Biosciences and Servier announced promising Phase 2/3 trial results for darovasertib, a selective PKC inhibitor, combined with crizotinib in the treatment of metastatic uveal
As reported on Healthline, a man in Norway has entered sustained HIV remission following a stem cell transplant, becoming one of a small number of
Two University of Michigan professors, Jolanta Grembecka and her husband Tomasz Cierpicki, created the newly approved leukemia drug ziftomenib. Its recent FDA approval offers new
Sarepta Therapeutics has announced a significant regulatory milestone in its efforts to secure permanent FDA approval for two breakthrough Duchenne muscular dystrophy (DMD) treatments. As
Editor’s Note: Patient Worthy is honored to share this article, originally submitted by Camille Johnson. For chronic disease patients living with rare conditions and long-term
As reported on Cardiovascular Business, new long-term findings presented at the American College of Cardiology (ACC) 2026 meeting provide compelling evidence that early and continuous
A pivotal study recently published in the journal Gero Science has revealed new insights into how individual brain regions age and why some are more
Caring for Duchenne muscular dystrophy is about more than treatment- it's about adapting, supporting, and empowering every step of the journey. With the right combination of medical care, therapies, and daily support, individuals can maintain independence longer and improve overall quality of life. Awareness and understanding play a key role in ensuring those affected receive the comprehensive care they deserve. #dmdawareness #HealthcareEducation #PatientWorthy
We're honored to bring you this story-share from Tim, who discusses nearly two decades worth of experiences in the Moebius syndrome community. Read here:
patientworthy.com
Awareness Isn’t the Hard Part — What 18 Years in the Moebius Syndrome Community Has Taught Me Post author:Patient Worthy Contributor Post published:April 26, 2026 Post category:Moebius Syndrome Fo...
From Overlooked to Unstoppable: The Mendoza Story That Inspired a Nation bit.ly/4sYbEft Read now at PatientWorthy.com
#PatientWorthy #MultipleSclerosis #MS #football #NFLDraft
© Copyright 2024 Patient Worthy
Sign Up With a Patient Worthy Account and Share Your Rare Story
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
